Piper Sandler raised the firm’s price target on Idexx Laboratories (IDXX) to $775 from $700 following quarterly results. The firm keeps a Neutral rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- IDEXX Laboratories Reports Strong Q3 Earnings and Raises Guidance
- Idexx Laboratories price target raised to $805 from $765 at Morgan Stanley
- Idexx Laboratories price target raised to $750 from $710 at UBS
- Idexx Laboratories price target raised to $830 from $785 at BTIG
- Idexx Laboratories: Strong Financial Performance and Strategic Advancements Justify Buy Rating